Moleculin Biotech, Inc. Quarterly Debt-to-equity in % from Q3 2016 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Moleculin Biotech, Inc. quarterly Debt-to-equity history and growth rate from Q3 2016 to Q3 2024.
Moleculin Biotech, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 62 %, a 392% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	62	+49.4	+392%	Sep 30, 2024
Q2 2024	33.5	+21.1	+170%	Jun 30, 2024
Q1 2024	26.5	+15.5	+141%	Mar 31, 2024
Q4 2023	19.5	+9.44	+93.4%	Dec 31, 2023
Q3 2023	12.6	+3.53	+38.9%	Sep 30, 2023
Q2 2023	12.4	+3.87	+45.3%	Jun 30, 2023
Q1 2023	11	+2.32	+26.8%	Mar 31, 2023
Q4 2022	10.1	+0.31	+3.17%	Dec 31, 2022
Q3 2022	9.07	-5.18	-36.3%	Sep 30, 2022
Q2 2022	8.54	-12.9	-60.2%	Jun 30, 2022
Q1 2022	8.66	-28.7	-76.8%	Mar 31, 2022
Q4 2021	9.79	-69.2	-87.6%	Dec 31, 2021
Q3 2021	14.3	-64.9	-82%	Sep 30, 2021
Q2 2021	21.4	-50.4	-70.1%	Jun 30, 2021
Q1 2021	37.4	-19.7	-34.5%	Mar 31, 2021
Q4 2020	79	+26.5	+50.4%	Dec 31, 2020
Q3 2020	79.2	+31.9	+67.5%	Sep 30, 2020
Q2 2020	71.8	+30	+71.7%	Jun 30, 2020
Q1 2020	57	+15.5	+37.4%	Mar 31, 2020
Q4 2019	52.5	+18.1	+52.5%	Dec 31, 2019
Q3 2019	47.3	+18.5	+64.3%	Sep 30, 2019
Q2 2019	41.8	+19.9	+90.9%	Jun 30, 2019
Q1 2019	41.5	+27.4	+194%	Mar 31, 2019
Q4 2018	34.4	+19.7	+133%	Dec 31, 2018
Q3 2018	28.8	+14.9	+108%	Sep 30, 2018
Q2 2018	21.9	+8.54	+63.8%	Jun 30, 2018
Q1 2018	14.1	+1.5	+11.9%	Mar 31, 2018
Q4 2017	14.8	+4.35	+41.8%	Dec 31, 2017
Q3 2017	13.9	+0.45	+3.35%	Sep 30, 2017
Q2 2017	13.4			Jun 30, 2017
Q1 2017	12.6			Mar 31, 2017
Q4 2016	10.4			Dec 31, 2016
Q3 2016	13.4			Sep 30, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.